Hurthle cell carcinoma in childhood: A retrospective analysis of five cases and review of pediatric literature.
antecedents of other diseases
cytologic features
relative prevalence of Hurthle cell cancer
risk levels
thyroid cancer histotypes
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
30
12
2019
revised:
17
03
2020
accepted:
18
03
2020
pubmed:
3
7
2020
medline:
15
12
2020
entrez:
3
7
2020
Statut:
ppublish
Résumé
the available studies on Hurthle cell carcinoma (HCC) in pediatric age are scarce and based on isolated case reports. Aims of the present study were to review the available pediatric literature on HCC (2000-2019), to describe the cohort of children with this cancer histotype, and to estimate its relative prevalence in pediatric age. We retrospectively reconstructed an HCC course in five patients < 19 years who were identified in our departments during the period 2000-2019, and we reviewed the available pediatric studies on this differentiated thyroid cancer (DTC) variant. HCC occurred with a relative prevalence of 5.8% at a median chronological age of 12.5 years. None of HCC patients exhibited, at diagnosis, thyroid dysfunction, extensive lateral neck disease, or distant metastases, and all showed a persistent remission over time. Three patients showed, at diagnosis, antecedents of other diseases (Hashimoto's thyroiditis, neurofibromatosis type 1, and osteosarcoma). (1) In childhood, the relative prevalence of HCC among different thyroid cancer histotypes is 5.8%, that is close to the one previously reported both in the general population and in other less numerous children's cohorts; (2) HCC may develop even early, at the age of 7; (3) in childhood, HCC does not seem to have a more aggressive behavior when compared with other DTC histotypes; (4) antecedents of other diseases are not infrequent in the history of children with HCC.
Sections du résumé
BACKGROUND
the available studies on Hurthle cell carcinoma (HCC) in pediatric age are scarce and based on isolated case reports. Aims of the present study were to review the available pediatric literature on HCC (2000-2019), to describe the cohort of children with this cancer histotype, and to estimate its relative prevalence in pediatric age.
PROCEDURE
We retrospectively reconstructed an HCC course in five patients < 19 years who were identified in our departments during the period 2000-2019, and we reviewed the available pediatric studies on this differentiated thyroid cancer (DTC) variant.
RESULTS
HCC occurred with a relative prevalence of 5.8% at a median chronological age of 12.5 years. None of HCC patients exhibited, at diagnosis, thyroid dysfunction, extensive lateral neck disease, or distant metastases, and all showed a persistent remission over time. Three patients showed, at diagnosis, antecedents of other diseases (Hashimoto's thyroiditis, neurofibromatosis type 1, and osteosarcoma).
CONCLUSIONS
(1) In childhood, the relative prevalence of HCC among different thyroid cancer histotypes is 5.8%, that is close to the one previously reported both in the general population and in other less numerous children's cohorts; (2) HCC may develop even early, at the age of 7; (3) in childhood, HCC does not seem to have a more aggressive behavior when compared with other DTC histotypes; (4) antecedents of other diseases are not infrequent in the history of children with HCC.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28300Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Bremer AA, Feldman BJ, Iezza G, Clark OH, Rosenthal SM. Report of a Hürthle cell neoplasm in a peripubertal girl. Thyroid. 2007;17:175-178.
Francis GL, Waguespack SG, Bauer AJ, et al. American thyroid association guidelines task force management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid. 2015;25:716-759.
Haroon Al, Rasheed MR, Xu B. Molecular alterations in thyroid carcinoma. Surg Pathol Clin. 2019;12:921-930.
Barnabei A, Ferretti E, Baldelli R, Procaccini A, Spriano G, Appetecchia M. Hurthle cell tumours of the thyroid: personal experience and review of the literature. Acta Otorhinolaryngol Ital. 2009;29:305-311.
Siddiqui AR, Karanauskas S. Hürthle cell carcinoma in an autonomous thyroid nodule in an adolescent. Pediatr Radio. 1995;25:568-569.
Yalla NM, Reynolds LR. Hürthle cell thyroid carcinoma presenting as a “hot” nodule. Endocr Pract. 2011;17:e68-72.
Peiretti V, Mussa A, Feyles F, et al. Thyroid involvement in two patients with Bannayan-Riley-Ruvalcaba syndrome. J Clin Res Pediatr Endocrinol. 2013;5:261-265.
Goffredo P, Roman SA, Sosa JA. Hurthle cell carcinoma: a population-level analysis of 3311 patients. Cancer. 2013;119:504-511.
Chen H, Nicol TL, Zeiger MA, et al. Hürthle cell neoplasms of the thyroid: are there factors predictive of malignancy. Ann Surg. 1998;227:542-546.
Kochummen E, Tong S, Umpaichitra V, Chin VL. A unique case of bilateral Hürthle cell adenoma in an adolescent. Horm Res Paediatr. 2017;87:136-142.
Bauer AJ, Tuttle RM, Francis GL. In: Pescovitz OH, ed. Thyroid Nodules and Thyroid Cancer in Children and Adolescents. Philadelphia, PA: Lippincott Williams & Wilkins; 2004:522-547.
Corrias A, Mussa A, Grossi A, Cappa M. Thyroid nodules and carcinoma. Thyroid Diseases in Childhood: Recent Advances from Basic Science to Clinical Practice. 2015:159-180.
Wasniewska M, Corrias A, Salerno M, et al. Outcomes of children with hashitoxicosis. Horm Res Paediatr. 2012;77:36-40.
Aversa T, Valenzise M, Corrias A, et al. Underlying Hashimoto's thyroiditis negatively affects the evolution of subclinical hypothyroidism in children irrespective of other concomitant risk factors. Thyroid. 2015;25:183-187.
Wasniewska M, Aversa T, Salerno M, et al. Five-year prospective evaluation of thyroid function in girls with subclinical mild hypothyroidism of different etiology. Eur Endocrinol. 2015;173:801-808.
Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid. 2017;27:1341-1346.
Ahmadi S, Stang M, Jiang XS, Sosa JA. Hürthle cell carcinoma: current perspectives. Onco Targets and Ther. 2016;9:6873-6884.
Bhattacharyya N. Survival and prognosis in Hürthle cell carcinoma of the thyroid gland. Arch Otolaryngol Head Neck Surg. 2003;129:207-210.
Arici C, Erdogan O, Altunbas H, et al. Differentiated thyroid carcinoma in children and adolescents: clinical characteristics, treatment and outcome of 15 patients. Horm Res. 2002;57:153-156.
Haveman JW, van Tol KM, Rouwé CW, Piers DA, Plukker JT. Surgical experience in children with differentiated thyroid carcinoma. Ann Surg Oncol. 2003;10:15-20.
Kowalski LP, Gonçalves Filho J, Pinto CA, Carvalho AL, de Camargo B. Long-term survival rates in young patients with thyroid carcinoma. Arch Otolaryngol Head Neck Surg. 2003;129:746-749.
Dzodic R, Buta M, Markovic I, et al. Surgical management of well-differentiated thyroid carcinoma in children and adolescents: 33 years of experience of a single institution in Serbia. Endocr J. 2014;61:1079-1086.
Kuo EJ, Roman SA, Sosa JA. Patients with follicular and Hurthle cell microcarcinomas have compromised survival: a population level study of 22,738 patients. Surgery. 2013;154:1246-1253.
Besic N, Schwarzbartl-Pevec A, Vidergar-Kralj B, Crnic T, Gazic B, Marolt Music M. Treatment and outcome of 32 patients with distant metastases of Hürthle cell thyroid carcinoma: a single-institution experience. BMC Cancer. 2016;16:162.
Zirilli G, Cannavò L, Vermiglio F, Violi MA, De Luca F, Wasniewska M. Differentiated thyroid carcinoma presentation may be more aggressive in children and adolescents than in young adults. Ital J Pediatr. 2018;44:13-17.
Cohen PR. Segmental neurofibromatosis and cancer: report of triple malignancy in a woman with mosaic neurofibromatosis 1 and review of neoplasms in segmental neurofibromatosis. Dermatol Online J. 2016;15:22.
van Lierop ZYGJ, Jentjens S, Anten MHME, et al. Thyroid gland 18F-FDG uptake in neurofibromatosis type 1. Eur Thyroid J. 2018;7:155-161.
Finke I, Scholz-Kreisel P, Hennewig U, Blettner M, Spix C. Radiotherapy and subsequent thyroid cancer in German childhood cancer survivors: a nested case-control study. Radiat Oncol. 2015;310:219-225.
Bhatti P, Veiga LH, Ronckers CM, et al. Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study. Radiat Res. 2010;174:741-752.